Exicure Shares Rise on Positive Phase 2 Data for Burixafor

EXICURE, INC. shares are trading higher after the company announced positive Phase 2 trial results for burixafor in treating multiple myeloma, demonstrating a high success rate in stem cell mobilization and an excellent safety profile.